Skip to main content
Federal Lobbying Data · Senate LDA Filings · Updated Quarterly
LobbySpend

Boehringer Ingelheim

Pharmaceutical & Health Products · Lobbying Client

Reviewed by LobbySpend Editorial Team · Updated
C
Influence Score
50/100
Moderate Influence
$5.4M
Total Lobby Spend
4
Policy Issues
4
Lobbyists
1
Revolving Door

Boehringer Ingelheim's Federal Lobbying Record

Boehringer Ingelheim's $5.4M in disclosed federal lobbying puts it in the mid-tier of registered filers. Spending in the seven-figure range is common for established trade groups, mid-size corporations, and advocacy organizations that maintain a steady but not aggressive presence on Capitol Hill.

Across the 5-year window from 2020 to 2024, Boehringer Ingelheim's annual disclosed lobbying spend has climbed meaningfully — from $906K in 2020 to $1.1M in 2024, a change of +18%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.

Boehringer Ingelheim's disclosed lobbying focuses on a narrow 4-issue footprint. A focused issue list usually means the organization concentrates its federal engagement on a small set of bills or rulemakings directly relevant to its core business.

1 of 4 lobbyists reported by Boehringer Ingelheim (25%) disclose prior federal government service. That share is common at established government affairs operations that explicitly hire from agency and committee staff.

Among the named bench, lobbyists with disclosed prior federal service include Michael K. Brown (Former Special Counsel, White House Office). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.

Within the Pharmaceutical & Health Products sector, Boehringer Ingelheim ranks #28 of 34 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.7M. Boehringer Ingelheim's $5.4M sits 68% below the sector average.

Boehringer Ingelheim's LobbySpend Influence Score of 50/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.

Every figure above is sourced from Senate lobbying disclosure filings submitted under the Lobbying Disclosure Act of 1995. Per-issue dollar splits and covered-position flags are filer-reported and may be amended after initial submission.

Track Boehringer Ingelheim's lobbying filings

Subscribe for LobbySpend updates by email. No spam, unsubscribe anytime.

Annual Lobbying Spend

Policy Issues

Government Entities Contacted

Securities & Exchange Commission
Dept of Justice
Dept of Energy
Small Business Administration
Office of the U.S. Trade Representative
Dept of State
Dept of Commerce

Recent Filings

PeriodRegistrantIssuesLobbyistsAmount
2024 Oct-DecInvariant LLC
GOVHCR
1$294K
2024 Jul-SepCapitol Counsel
GOVHCRPHA
1$215K
2024 Apr-JunVan Scoyoc Associates
PHAMEDGOV+1
4$251K
2024 Jan-MarSquire Patton Boggs
HCRPHA
2$274K
2023 Oct-DecHolland & Knight
MEDPHAHCR
2$228K
2023 Jul-SepSteptoe & Johnson
MEDGOVPHA+1
3$263K
2023 Apr-JunHolland & Knight
PHAHCR
2$259K
2023 Jan-MarSteptoe & Johnson
GOVHCR
3$269K

Boehringer Ingelheim Lobbying FAQ

Boehringer Ingelheim has spent $5.4M on federal lobbying across 4 policy areas. This includes spending on registered lobbyists and direct government contacts.

Boehringer Ingelheim lobbies on 4 policy issues, including Health Issues, Pharmacy, Medical/Disease Research, Government Issues. These disclosures are filed quarterly with the Senate Office of Public Records.

Boehringer Ingelheim has an Influence Score of 50/100 (Grade C). This proprietary score is based on total lobby spend (40%), policy issue breadth (30%), and revolving door connections (30%).

Boehringer Ingelheim employs 4 registered lobbyists, of whom 1 have revolving door connections, meaning they previously held government positions before becoming lobbyists.

Boehringer Ingelheim has contacted 7 government entities as part of their lobbying activities, including Securities & Exchange Commission, Dept of Justice, Dept of Energy.

Sources: Senate Office of Public Records (LDA), OpenSecrets.org
Last updated:

Lobbying data is sourced from quarterly Lobbying Disclosure Act (LDA) filings with the Senate Office of Public Records. Influence Scores combine total spend (40%), issue breadth (30%), and revolving door connections (30%). Filings may be amended after initial submission.